Analysis of the clinical manifestations of cerebral stroke in patients with the novel coronavirus infection (COVID-19)

2020 ◽  
pp. 30-45
Author(s):  
Vladislav V. Andreev ◽  
Alexander Y. Podunov ◽  
Daniil S. Lapin ◽  
Zarema L. Gilyaeva ◽  
Ekaterina N. Nikiforova ◽  
...  
Keyword(s):  
Lung Tissue ◽  
Hemorrhagic Stroke ◽  
Clinical Laboratory ◽  
Clinical Manifestations ◽  
Community Acquired Pneumonia ◽  
Control Group ◽  
Cerebral Stroke ◽  
The Novel ◽  
Coronavirus Infection ◽  
Novel Coronavirus

Objective: To improve the diagnosis and treatment of acute cerebrovascular accident in patients with community-acquired pneumonia caused by the novel coronavirus infection (COVID-19). Materials and methods: For the first time, clinical manifestations of strokes in patients with diagnosed new coronavirus infection (COVID-19) were analyzed in 130 patients. The study was conducted in two groups. The main group consisted of 69,2 % (n = 90) with a clinical and instrumental diagnosis: novel coronavirus infection in combination with stroke. The control group (30,8 %; n = 40) included the cases of ischemic and hemorrhagic stroke without signs of SARS-CoV-2. In both groups, the severity of the disease and pathogenetic subtypes were compared, and the features of the laboratory biochemical data were studied. Statistical analysis of the outcomes was carried out taking into account the severity of brain and lung tissue damage. Results: In patients with cerebral stroke against the background of the new coronavirus infection (COVID-19), the prevalence of ischemic stroke cases (86,4 %) was noted for undetermined (41,4 %) and cardioembolic (35,7 %) pathogenetic subtypes (according to TOAST) with localization in the carotid basin (89,7 %). In hemorrhagic stroke, parenchymal hemorrhage was observed with a greater frequency (54,5 %). The severity of the diagnosed strokes according to the NIHSS scale was up to 13,16 (8,80) points with less severe brain damage — Glasgow coma scale (14,0 (12,0 15,0). In the group of the patients, a widespread lesion of the lung tissue was diagnosed in 82,2 % of cases. No significant increase in the incidence of clinically significant manifestations of systemic and organ hypercoagulation was established. Conclusions: In stroke patients with COVID-19, ischemic manifestations with undetermined and cardioembolic subtypes without age and gender features prevail, with no differences in the severity of the course and a large number of favorable outcomes. A high activity of inflammatory and infectious changes was established by clinical laboratory.

FEATURES OF THE COURSE AND TACTICS OF MANAGING CHILDREN WITH KIDNEYS AND URINARY TRACT DISEASES DURING THE PANDEMIC OF NEW CORONAVIRUS INFECTION COVID-19

2021 ◽  
Vol 100 (4) ◽  
pp. 74-79
Author(s):  
I.M. Kagantsov ◽  
◽  
V.V. Sizonov ◽  
V.G. Svarich ◽  
K.P. Piskunov ◽  
...  
Keyword(s):  
Age Groups ◽  
Clinical Manifestations ◽  
Routine Care ◽  
The Novel ◽  
Urinary System ◽  
Death Rates ◽  
Global Pandemic ◽  
Coronavirus Infection ◽  
Novel Coronavirus ◽  
Significant Health

The novel coronavirus infection (SARS-CoV-2), which first appeared in Wuhan, China in December 2019, has been declared a global pandemic by WHO. COVID-19 affects people of all age groups. The disease in children is usually asymptomatic or mild compared to adults, and with a significantly lower death rates. Data on kidney damage in children with COVID-19, as well as the effect of coronavirus infection on the course of diseases of the genitourinary system, are limited, the risks of contracting a new coronavirus infection in children with significant health problems, including those with chronic kidney disease, remain uncertain. The pandemic has affected the activities of surgeons treating diseases of the urinary system in children. Since the prospects for the end of the pandemic are vague, it is necessary to formulate criteria for selecting patients who can and should be provided with routine care in the pandemic. The purpose of this review is to highlight the features of the clinical manifestations and treatment of children with COVID-19, occurring against the background of previous renal pathology or complicating its course.

Normoxic barotherapy in medical rehabilitation of patients after the novel coronavirus infection

2020 ◽  
pp. 29-35
Author(s):  
A. S. Kaisinova ◽  
A. N. Semukhin ◽  
A. V. Abramtsova ◽  
N. V. Efimenko ◽  
D. I. Velikanov ◽  
...  
Keyword(s):  
Rehabilitation Program ◽  
Medical Rehabilitation ◽  
Control Group ◽  
Spa Therapy ◽  
Blood Oxygen ◽  
The Novel ◽  
Physical And Mental Health ◽  
Blood Oxygen Saturation ◽  
Coronavirus Infection ◽  
Novel Coronavirus

The purpose of the study is to develop a medical rehabilitation program for the patients who have come through a new coronavirus infection in the resort of Pyatigorsk. Material and methods. In the conditions of the health center named after S.M. Kirov in Pyatigorsk, a branch of FSBI NCFSCC FMBA of Russia, there have been observed 52 patients who had the new coronavirus infection COVID-19 of moderate severity, at the age from 18 up to 65 years old. Two groups have been formed by simple randomization: in the main group, the patients received normoxic barotherapy against the background of traditional spa therapy for pulmonary patients; in the control group, the patients had only conventional therapy. Results. The inclusion of normoxic barotherapy in the complex of medical rehabilitation of patients who came through the novel coronavirus infection contributed to the increase of tolerance to exercise and improved blood oxygen saturation in 92,9 % of cases, restoration of impaired functions of bronchopulmonary apparatus in 89,3 % and physical and mental health in 85.7 % of cases, which was significantly higher in comparison to similar indicators in the control group. Conclusion. Medical rehabilitation of patients after the new coronavirus infection in the resort is justified and advisable.

scholarly journals Diagnosis and treatment of acute coronary syndrome during the novel coronavirus infection COVID-19 pandemic

2020 ◽  
Vol 25 (4) ◽  
pp. 3854
Author(s):  
A. M. Namitokov ◽  
O. P. Ishevskaya ◽  
V. I. Fetisova ◽  
E. D. Kosmacheva ◽  
V. A. Porkhanov
Keyword(s):  
Acute Coronary Syndrome ◽  
Clinical Manifestations ◽  
The Novel ◽  
Therapeutic Approaches ◽  
Susceptible Population ◽  
Coronary Syndrome ◽  
Cardiovascular Patients ◽  
Coronavirus Infection ◽  
Artery Disease ◽  
Novel Coronavirus

The novel coronavirus infection COVID-19 pandemic has spread to more than 180 countries. Cardiovascular patients belong to one of the susceptible population cohorts. There is a peculiar pathogenesis and variety of clinical manifestations of COVID-19, as well as difficulties with early diagnosis. Other unresolved issues are routing, surgery and therapy of such patients and comorbidities. Due to absence of well-defined algorithms and guidelines, the treatment of patients with acute coronary syndrome (ACS) in different countries is carried out differently. Interactions between antiviral and coronary artery disease medications are also not completely clear. Based on the available data, the main organizational and therapeutic approaches for ACS during the COVID-19 pandemic are reflected.

scholarly journals SARS-CoV-2 infection: Understanding the immune system abnormalities to get an adequate diagnosis

2021 ◽  
Author(s):  
Karen Medina-Quero ◽  
Omar Barreto-Rodriguez ◽  
Voltaire Mendez-Rodriguez ◽  
Anahí Sanchez-Moncivais ◽  
Ivette Buendia-Roldan ◽  
...  
Keyword(s):  
Immune System ◽  
Clinical Laboratory ◽  
Clinical Manifestations ◽  
Diagnostic Tools ◽  
The Novel ◽  
Virus Structure ◽  
Immune System Function ◽  
Incidence And Mortality ◽  
Close Relationship ◽  
Novel Coronavirus

COVID-19 is the current pandemic caused by the novel coronavirus, SARS-CoV-2, that emerged from China at the end of December 2019. The scientific community is making extraordinary efforts to understand the virus structure and the pathophysiology and immunological processes activated in the host, in order to identify biomarkers, diagnostic tools, treatments, and vaccines to decrease COVID-19 incidence and mortality. Various abnormalities have been noted during SARS-CoV-2 infection both in lymphoid and myeloid cells. Such abnormalities may disturb the immune system function and cause a massive inflammatory response that impairs tissue function. This review discusses the close relationship between the immune system abnormalities and the broad spectrum of clinical manifestations, including fibrosis, in the context of COVID-19 disease. Moreover, we described the current strategies for COVID-19 diagnosis, and we provide a summary of the most useful clinical laboratory parameters to identify severe COVID-19 patients.

Immune properties of lactoferrin and its protective role in new coronavirus infection COVID-19

2021 ◽  
pp. 22-26
Author(s):  
S. V. Orlova ◽  
E. A. Nikitina ◽  
E. V. Prokopenko ◽  
L. Yu. Volkova ◽  
A. N. Vodolazkaya
Keyword(s):  
Humoral Immunity ◽  
Acute Phase Protein ◽  
Clinical Manifestations ◽  
Protective Role ◽  
Viral Diseases ◽  
The Novel ◽  
Phase Protein ◽  
Nasal Secretions ◽  
Coronavirus Infection ◽  
Novel Coronavirus

Thousands of studies have been conducted to study the new SARS-CoV-2 coronavirus, its infectious properties, transmission routes and all associated with the clinical manifestations and severity of COVID-19, especially with potential treatments. Lactoferrin is a member of the transferrin family, which is synthesized by epithelial cells of mammalian internal glands and is widely present in various secretory fluids such as milk, saliva, tears, and nasal secretions. Lactoferrin is one of the components of the innate humoral immunity, regulates the functions of immunocompetent cells and is a acute phase protein. Lactoferrin has strong antioxidant and anti-inflammatory properties. This review assesses the possibility of using lactoferrin as a supplement in immunocorrective therapy programs for viral diseases, including the novel coronavirus infection COVID-19.

scholarly journals The Coronavirus Disease 2019 (COVID-19): A Review

2020 ◽  
pp. 1-9 ◽  
Author(s):  
Sheikh Salahuddin Ahmed
Keyword(s):  
Clinical Manifestations ◽  
Severe Illness ◽  
The Novel ◽  
Full Spectrum ◽  
Pcr Method ◽  
Coronavirus Infection ◽  
Novel Virus ◽  
Clinical Illness ◽  
Novel Coronavirus ◽  
Supportive Management

Many details of the emergence of 2019 novel coronavirus infection such as its origin, spread, epidemiology, full spectrum of clinical illness, treatment and mortality rate has not been clearly defined. This review focuses the epidemiological evidences, clinical manifestations, investigations and treatment provided to the admitted cases of the 2019 novel coronavirus pneumonia in various hospitals of Wuhan city and other regions in China. Information have been gathered mainly from relevant researches and papers that were published recently. Clinical manifestations included fever, non-productive cough, dyspnoea, myalgia, fatigue, radiographic manifestations of pneumonia and detection of the novel virus by RT-PCR method. Some patients rapidly developed acute respiratory distress syndrome, acute respiratory failure, and other serious complications with fatal outcomes. There are neither vaccines nor effective treatments for the disease caused by the virus, but efforts are typically confined to symptomatic and supportive management. Antivirals and corticosteroids were used in severe illness but had no effective outcome.

scholarly journals Effectiveness of immobilized probiotics for complex therapy of novel coronavirus infection COVID-19 in hospital settings

2020 ◽  
Author(s):  
NG Bomshteyn ◽  
YuV Bolotov ◽  
IA Kim ◽  
DV Trukhin
Keyword(s):  
Prospective Observational Study ◽  
Clinical Laboratory ◽  
The Novel ◽  
Complex Treatment ◽  
Open Label ◽  
Probiotic Treatment ◽  
Complex Therapy ◽  
Coronavirus Infection ◽  
The Russian Federation ◽  
Novel Coronavirus

Taking into account the gut–lung microbiota axis, the new probiotic treatment methods for COVID-19 are currently being discussed. There are effective medicinal preparations of domestic manufacture in the Russian Federation, the immobilized probiotics. The study was aimed to determine the effectiveness of the mixed immobilized probiotic containing the immobilized B. bifidum and lactobacilli L. plantarum (100 million CFU per dose) or the simple immobilized probiotic containing the immobilized B. bifidum (500 million CFU per dose) in the complex therapy of patients with COVID-19. During the open-label, prospective, observational study 70 patients with confirmed diagnosis of COVID-19 received complex treatment which included the immobilized probiotics. All patients were discharged from the hospital with imporoved health status, as well as with improved instrumental and laboratory indicators: body temperature returned to normal in all patients; shortness of breath, cough, feeling of chest tightening, myalgia and headache disappeared; the patients regained sense of smell and taste; the weakness decreased or disappeared (pathognomic symptom for COVID-19). The dynamics of clinical, laboratory and instrumental indicators reflecting the course of the novel coronavirus infection demonstrates the effectiveness of the used complex therapy. The immobilized probiotics may be recommended for the complex treatment of patients with COVID-19.

Kumis treatment in medical rehabilitation of patients with pneumonia associated with the novel coronavirus infection COVID-19

2021 ◽  
pp. 33-39
Author(s):  
Lira Talgatovna Gilmutdinova ◽  
Elvira Railevna Faizova ◽  
Aydar Rashitovich Gilmutdinov ◽  
Ruslan Ralifovich Garaev ◽  
Naufal Rabisovich Yanbukhtin ◽  
...  
Keyword(s):  
Well Being ◽  
Main Group ◽  
Medical Rehabilitation ◽  
Control Group ◽  
External Respiration ◽  
Forced Expiration ◽  
The Novel ◽  
Severity Of Depression ◽  
Coronavirus Infection ◽  
Novel Coronavirus

The results of evaluating the effectiveness of the use of kumis treatment in 64 patients who have had pneumonia associated with the novel coronavirus infection COVID-19 are presented. It was found that the use of kumis treatment in addition to the basic complex in 32 patients of the main group has led to an increase in exercise tolerance by 13.6 % (p < 0,05), a decrease in the severity of shortness of breath by 36.3 % (p < 0.05), and contributed to the improvement of the parameters of the function of external respiration with an increase in the vital capacity of the lungs by 14,4 % (p < 0,05), the volume of forced expiration — by 24,5 % (p < 0,05). Against the background of kumis treatment, the patients of the main group showed a significant decrease in the severity of depression and anxiety — by 62.5 % (p < 0.05) and by 62.3 % (p < 0,05), respectively, an improvement in the parameters of «well-being» by 62,2 % (p < 0.05), «activity» — by 37,6 % (p < 0,05), «mood» — by 35,5 % (p < 0,05), compared to the initial values. The dynamics of parameters in the patients of the control group against the background of the basic complex turned out to be less significant in comparison with the main group.

scholarly journals Study of the effectiveness of methylprednisolone at different stages of inpatient care for patients with pneumonia caused by a new COVID-19 coronavirus infection

2020 ◽  
Author(s):  
EE Arinina ◽  
RT Tairova ◽  
AB Berdalin ◽  
SS Gujev ◽  
NA Glotova ◽  
...  
Keyword(s):  
Intensive Care Unit ◽  
Inpatient Care ◽  
Brain Research ◽  
Medical Ward ◽  
Control Group ◽  
The Novel ◽  
Cytokine Storm ◽  
Coronavirus Infection ◽  
Novel Coronavirus ◽  
Federal Center

Glucocorticoid therapy for a cytokine storm is one of the mainstays of managing the novel coronavirus disease COVID-19. The aim of this study was to evaluate the efficacy of methylprednisolone at different stages of medical care: in an intensive care unit (ICU) vs. a medical ward setting. Methylprednisolone therapy was delivered to 54 patients, amounting to 9% of the total patients hospitalized to the Federal Center of Brain Research and Neurotechnology of FMBA, Russia. Twenty-eight patients received methylprednisolone in the ICU setting; 26 patients, in a medical ward setting. The control group comprised 14 patients. Methylprednisolone was administered continuously, intravenously at 250 mg per day over the course of 3 days; the total dose was 750 mg. The analysis revealed a significant reduction in mortality in the group receiving methylprednisolone in a medical ward setting (7.7%) in comparison with the group receiving the drug in ICU (67.9%) and the control group (42.9%, р<0.001). The need for mechanical ventilation was lower in the group receiving methylprednisolone in a medical ward (2 (7.7%), 20 (71.4%) and 7 (50%) cases, respectively, р<0.001). Thus, preventive anti-inflammatory methylprednisolone therapy for delivered in a medical ward setting reduces hospital mortality and the need for MV in patients with COVID-19-induced pneumonia.

Sign in / Sign up

Export Citation Format

Share Document